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Schizophrenia (SZ) is a severe psychiatric illness associated with an elevated risk for developing Alzheimer’s disease
(AD). Both SZ and AD have white matter abnormalities and
cognitive deficits as core disease features. We hypothesized
that aging in SZ patients may be associated with the development of cerebral white matter deficit patterns similar to
those observed in AD. We identified and replicated agingrelated increases in the similarity between white matter deficit patterns in patients with SZ and AD. The white matter
“regional vulnerability index” (RVI) for AD was significantly higher in SZ patients compared with healthy controls in both the independent discovery (Cohen’s d = 0.44,
P = 1·10–5, N = 173 patients/230 control) and replication
(Cohen’s d = 0.78, P = 9·10–7, N = 122 patients/64 controls)
samples. The degree of overlap with the AD deficit pattern
was significantly correlated with age in patients (r = .21 and
.29, P < .01 in discovery and replication cohorts, respectively)
but not in controls. Elevated RVI-AD was significantly associated with cognitive measures in both SZ and AD. Disease
and cognitive specificities were also tested in patients with
mild cognitive impairment and showed intermediate overlap.
SZ and AD have diverse etiologies and clinical courses; our
findings suggest that white matter deficits may represent a
key intersecting point for these 2 otherwise distinct diseases.
Identifying mechanisms underlying this white matter deficit pattern may yield preventative and treatment targets for
cognitive deficits in both SZ and AD patients.

Introduction
Compared with the general population, individuals with
schizophrenia (SZ) have a significantly higher risk (2–4
times) of developing Alzheimer’s disease (AD) and other
dementias.1 As the hallmark neuropathological features
of AD are not typically found in younger SZ patients,2,3
this elevated risk for AD remains unexplained. Literature
on this topic inevitably invokes Kraepelin’s one-hundredyear-old term dementia praecox, describing the intellectual decline and observed neurodegeneration in some
SZ postmortem examinations.4 However, the historical
definition of SZ5,6 and the modern epidemiological literature1,7 do not offer a mechanistic explanation for the
higher rate of AD development in SZ patients.
Patients with AD and SZ both express complex anatomical and cognitive deficits but with nonoverlapping
clinical presentations. AD is characterized by a relatively
rapid progression with illness onset occurring during the
sixth to eighth decades of life. In contrast, SZ typically
emerges between late adolescence and early adulthood
with rapid worsening of cognitive deficits following illness
onset and a gradual aging-related decline afterward.8–10
The dominating etiological pathways for SZ and AD
are likewise nonoverlapping. The prevailing hypothesis
in AD posits neuronal atrophy due to the accumulation
of β-amyloid (Aβ) plaques and τ-neurofibrillary tangles.
The prevailing hypotheses in SZ are dysfunctions in the
dopamine, glutamate, and other neurotransmitter circuits.11–13 AD and SZ are distinct in their clinical presentations; however, we may have overlooked an important
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Materials and Methods
Sample Characteristics
The AD and MCI deficit patterns were derived from
datasets collected and distributed by the ADNI. We
chose 3 independent SZ samples: a sample of patients
and controls from the Baltimore, MD area to serve as
the discovery sample; a sample of patients and controls
from Beijing, China, to serve as the replication sample;
and a meta-analytical sample assessed by ENIGMA-SZ
198

workgroup to serve as another replication sample. The
ethnic and geographical diversity of these samples was
meant to reduce cohort-specific variances in diagnosis,
treatment, and other factors. All DTI data were processed
using a consistent ENIGMA-DTI workflow33 and passed
comprehensive QA and QC steps. Detailed demographic
(supplementary tables S1 and S2) and imaging information (supplementary table S3) are in the supplementary
information. Briefly:
ADNI Samples: AD and MCI. We downloaded demographic, diagnostic, and imaging data for participants in
ADNI-2 protocols (http://adni.loni.usc.edu). The details of
the site and imaging protocols are provided in the SI. The DTI
data passed ENIGMA QA/QC steps for 218 participants.
This sample included 53 healthy controls (M/F = 24/29,
age = 72.77 ± 7.57), 117 MCI (M/F = 73/44, age = 72.70 ±
7.67), and 48 AD (M/F = 29/19, age = 72.57 ± 7.67) patients. The cognitive data included: Mini Mental Status
Examination (MMSE),34 Clinical Dementia Rating Scale
Sum-of-Boxes (CDR-SOB),35 and Alzheimer’s Disease
Assessment Scale-Cognitive subscale (ADAS-Cog).36
Discovery Sample. The sample consisted of 173 SZ patients (M/F = 122/51, age = 36.0 ± 12.7) and 210 controls (M/F = 119/111, age = 38.2 ± 13.0) from the Greater
Baltimore area for whom DTI data passed ENIGMA
QA/QC requirements. Patients were recruited from
community psychiatric clinics and diagnosed with either DSM-IV schizophrenia or schizoaffective disorder.
Controls had no Axis I psychiatric disorder. Cognition
was evaluated by the Digit Symbol Coding task of
the WAIS-337 to assess processing speed and the Digit
Sequencing Test38 to assess working memory (supplementary table S2). The clinical and DTI protocol information
have been reported9 and are further described in SI.
Replication Sample. The sample consisted of 122
SZ patients (M/F = 57/65, 38.2 ± 13.3) and 78 controls (M/F = 37/41, 39.2 ± 14.0), recruited from Beijing
Huilongguan Hospital, Beijing, China for whom DTI
data passed ENIGMA QA/QC requirements. Controls
were recruited through local advertisements. Patients met
DSM-IV criteria for SZ, and all participants were Han
Chinese. DTI data were collected using a 3T Siemens
MRI scanner. The clinical and DTI protocol information
have been reported32 and are further described in SI.
Meta-Data Replication Sample From ENIGMA. The
worldwide aggregate data from the largest meta-analysis
of DTI in SZ performed by ENIGMA39 were used as
the second replication sample. This sample consisted of
1963 SZ patients and 2359 controls from 29 international
studies.39 The clinical, DTI, and harmonization information have been described previously.39
Image Processing
DTI data for all cohorts were processed uniformly using
the ENIGMA-DTI analysis pipeline (https://www.nitrc.
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shared feature between AD and SZ such as the profound
white matter impairment in both illnesses.
Despite etiological and clinical differences, impaired
brain white matter microstructure, measured as a reduction in fractional anisotropy (FA) derived from diffusion tensor imaging (DTI), is prominent in both
disorders: white matter deficits are present before disease onset and track with the rise in cognitive decline
and symptom severity.10,14–16 In AD, the illness-related
pathology is characterized by distinct temporal and regional patterns that track with the accumulation of Aβ
plaques and τ-neurofibrillary tangles.17 AD pathology is
considered a direct factor in axonal damage and the regional specificity of FA deficits, independent of age and
hyperintensive white matter lesion burden.18 Reduced FA
values in pathways serving higher cognitive function are
associated with higher cognitive deficits in AD.16 In SZ,
regional FA deficits also occur in specific temporal and
regional patterns that precede symptoms and are associated with cognitive deficits.19–30 A large and inclusive
meta-analytic SZ study performed by the Enhancing
Neuro Imaging Genetics Meta-Analysis (ENIGMA)
consortium showed that patients have reproducible and
stable patterns of white matter deficits.31 Here, we aimed
to evaluate the similarity of the white matter deficit patterns between AD and SZ as a potential explanation for
the higher risk of developing AD in SZ patients.
To capture the similarity between white matter deficit
patterns, we calculated a white matter regional vulnerability index (RVI)32 for AD using data from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI). RVI quantifies
the similarity between white matter patterns of any individual and the deficit pattern observed in AD. We tested
the hypothesis that SZ patients have elevated RVI scores
for AD in independent discovery, replication, and metaanalytical samples. We tested specificity by contrasting
deficit patterns in AD with patterns in mild cognitive impairment (MCI). MCI has elevated risks for developing
AD but itself is not AD; thus, we used the similarity to
MCI as a control for testing age-related anatomical deficits
that are AD specific. We further tested a reverse association by showing elevated SZ white matter deficit patterns
in AD patients. Finally, we tested the hypothesis that RVIdefined white matter patterns impact the cognitive deficits
most characteristic of SZ and AD.

White Matter Schizophrenia and Alzheimer’s Disease

org/projects/enigma_dti)33; details are described in SI.
The per-tract effect size for the FA, shown in figure 1
(see legend for tract names), was calculated by averaging
values along tract regions of interest in both hemispheres.
All data were corrected for age, sex, and age by sex interaction during normalization to increase compatibility
among the cohorts.
Statistical Analysis

Cognition ∼ A + βsz · DXsz or βAD · DXAD

+ βRVI−AD · RVI − ADor βRVI−SZ · RVI − SZ

where “cognition” stands for the cognitive measures and
DX for diagnosis (coded as follows: in the SZ sample:
SZ = 1, control = 0; in the ADNI sample: AD = 1, control = 0). Collinearity was examined using the variance
inflation factor (<5.0 is deemed acceptable). Effects of
symptoms, antipsychotic medication dose, and smoking

Fig. 1. The pattern of white matter microstructural deficits across 22 white matter regions as ranked by their Cohen’s d effect sizes
(patients < controls) in fractional anisotropy in each sample. The tabulated statistics are presented in supplementary table S5. The
black line indicates the best linear fit for each disease; regional vulnerability index (RVI) (eg, for AD) is essentially a calculation of the
correlation coefficient between this line for AD and the FA of these 22 regions in an individual. Note: ACR, Anterior Corona Radiata;
ALIC, Anterior Limb of Internal Capsule; BCC, Body of Corpus Callosum; CC, Corpus Callosum; CGC, Cingulum; CR, Corona
Radiata; CST, Cortico-Spinal Tract; EC, External Capsule; FX, Fornix, GCC, Genu of Corpus Callosum, IC, Internal Capsule; IFO,
Inferior Frontal Occipital fasciculus; PCR, Posterior Corona Radiata; PLIC, Posterior Limb of Internal Capsule; PTR, Posterior
Thalamic Radiation; RLIC, Retrolenticular Limb of the Internal Capsule; SCC, Splenium of Corpus Callosum; SCR, Superior Corona
Radiata; SFO, Superior Fronto-Occipital Fasciculus; SLF, Superior Longitudinal Fasciculus; SS, Sagittal Striatum; UNC, Uncinate
Fasciculus.
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RVI Calculation. The RVI is a simple measure of the
similarity between an individual and the expected deficit
pattern derived from a representative disease sample.31,32
In this study, it is calculated as a correlation between
an individual’s pattern of FA in the 22 white matter regions and the expected pattern of a disease condition.
Regional FA for each tract was z-normalized by calculating the residual values after the regression of age
and sex effects, and then subtracting the average value
for a region and dividing it by the standard deviation
calculated from the sample’s healthy controls. This produced a vector of z-values with 22 regional values for
every individual. The ADNI sample was used to calculate Cohen’s d effect sizes for AD and MCI patients vs
controls (figure 1A). RVI-AD is a scalar correlation coefficient between region-wise z values for the individual
and the AD-control effect sizes. Higher RVI values in
SZ patients would imply a higher similarity of the white
matter regional deficit patterns in SZ toward that of
AD. RVI-SZ was calculated using effect sizes from the
ENIGMA sample.39

Hypothesis Testing. Effect sizes of white matter FA in
AD and MCI calculated from the ADNI sample were
used to derive RVI-AD and RVI-MCI in SZ patients and
controls. Hypothesis testing was performed in 3 steps: (1)
Testing if RVI-AD is elevated in SZ patients in the discovery sample, followed by confirmatory testing in 2 replication cohorts and age-group analysis; specificity testing
was performed using RVI-MCI values. (2) Testing the reverse association where RVI-SZ based on the ENIGMA
SZ pattern is significantly elevated in AD patients; specificity testing was performed in MCI patients. (3) Testing
that RVI-AD is associated with cognitive deficits in AD
patients and SZ patients.
The age-group analysis was tested by dividing the discovery and replication cohorts into 4 age groups: 18–29,
30–39, 40–49, and 50–65 (supplementary table S5) and
evaluating patient-control differences within each age
category.
The associations between RVI and cognition were
tested using a linear model:

P. Kochunov et al

status (modeled as current smokers or not) were similarly
explored in regression analyses. Group comparisons of
RVI values were performed by ANOVA. All statistical
significance thresholds were corrected for multiple comparisons by false discovery rates (FDR).
Results

Five samples were analyzed to test the above hypotheses—the ADNI samples40 for AD and MCI and 3 SZ
samples—a discovery sample from Baltimore, MD; a
replication sample from Beijing, China; and a replication
sample from the worldwide meta-sample from ENIGMA,
which is the largest white matter imaging sample in SZ.41
Each sample had its own healthy controls. Details on
sample size, demographic (supplementary tables S1 and
S2), and imaging (supplementary table S3) information
are in the Methods section and supplementary information. White matter microstructures were measured by FA
of DTI. The ranks of regional FA effect sizes between patients and controls for each cohort are shown in figure 1
and supplementary table S4. In AD, the largest effect
sizes were in the fornix (FX) followed by the splenium of
the corpus callosum (SCC) (figure 1A). In MCI, the largest effect sizes were in the SCC and FX (figure 1B). In
the 3 SZ cohorts, patients showed the largest effect sizes
in the anterior corona radiata (ACR), anterior limb of
the internal capsule (ALIC), FX, and body of the corpus
callosum (BCC) (figures 1C–E). The regional patientcontrol effect sizes in the discovery and replication cohorts were significantly correlated with those reported by
ENIGMA (r = .94 and .85, P < .01, for discovery and
replication cohorts, respectively).

SZ patients had significantly higher RVI-AD than controls (Cohen’s d = 0.44, t = 4.5, P = 1·10–5) figure 2A).
RVI-AD showed significant and positive Spearman correlations with age in SZ patients (r = .21, P < .001) but
not in controls (r = −.03, P = .8). SZ patients had significantly higher RVI-AD compared with controls starting at
age 30 (figure 3A).
Elevated White Matter RVI-AD in SZ in the
Replication Sample
SZ patients again showed significantly higher RVI-AD
than controls (Cohen’s d = 0.78, t = 5.1, P = 9·10–7)
(figure 2B). There were no significant differences between
the discovery and replication cohorts in RVI-AD (P = .07)
(compare figure 2A vs 2B). SZ patients had significantly
higher RVI-AD compared with controls starting at age
40 (figure 3A). The significant correlations of RVI-AD
with age were also replicated in SZ patients (r = .29, P <
.001) (figure 3B). The correlation between RVI-AD and
age was not significant in controls (r = .18, P = .2).
Replication of Elevated White Matter RVI-AD in SZ
Using ENIGMA Sample
The ENIGMA SZ pattern of regional white matter
deficits was significantly correlated with the pattern for
white matter deficits in AD (r = .55, P = .01) (figure 4A).
The RVI-AD (calculated from ADNI) and RVI-SZ (calculated from ENIGMA) in SZ patients were highly
correlated (r = .65, P = 10–25) (figure 4C). Therefore,
despite the very different age ranges, etiologies, and
neuropathologies, the white matter deficit patterns in SZ
patients showed significantly elevated similarity to white

Fig. 2. Patient-control differences in the average RVI-AD and RVI-MCI values for the discovery and replication cohorts. Note: RVI,
regional vulnerability index; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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Patterns of Regional White Matter Deficits in AD,
MCI, and SZ

Elevated White Matter RVI-AD in SZ in the
Discovery Sample

White Matter Schizophrenia and Alzheimer’s Disease

matter deficit patterns observed in AD patients across the
samples.
Relative Specificity Testing by Comparing With MCI
SZ patients also showed elevated RVI-MCI in both the
discovery (t = 3.3, P = .002) and replication sample
(t = 3.8, P = 2·10–4) (figure 2B). The ENIGMA SZ pattern of white matter deficits was not significantly correlated with those in MCI (r = .10, P = .6) (figure 4B).
The correlation between RVI-MCI and RVI-SZ was also
significant (r = .31, P = 10–4) (figure 4D) but the r value
was significantly smaller than the correlation between
RVI-AD and RVI-SZ (z test of the correlation coefficients = 3.5, P = 4·10–4).
Testing the Reverse Association: Elevated RVI-SZ in AD
RVI-SZ values were derived from the ENIGMA SZ
sample and used to calculate RVI-SZ in AD and MCI
patients and controls in ADNI. RVI-SZ was significantly
higher in AD patients compared with MCI patients
(P = .009) and normal controls (P = 8·10–5) (average
RVI-SZ = 0.15 ± 0.04, 0.00 ± 0.3, and −0.06 ± 0.4 for AD,
MCI, and controls, respectively). MCI patients showed
no significant difference in average RVI-SZ values compared with controls (P = .21).
RVI-AD on Cognition and Clinical Characteristics
Processing speed has been considered the cognitive
measure most robustly associated with schizophrenia42,43
and schizophrenia-related white matter deficits.9,44 We

found that RVI-AD significantly correlated with processing speed in the discovery (r = −.34, P = 1·10–4) and
replication samples (r = −.27, P = 2·10–4). One of the
standard tests for cognitive deficits for AD is the ADASCog.45 RVI-AD was significantly and positively correlated with the ADAS-Cog in the full ADNI sample
(r = .42, P = 10-10). Interestingly, RVI-SZ was also significantly correlated with ADAS-Cog in the full ADNI
sample (r = .33, P = 1·10–6). Finally, psychiatric symptoms were measured in the discovery and replication samples using the Brief Psychiatric Rating Scale (BPRS). No
significant associations between RVI-AD and BPRS total
or any subscale scores were detected (all r < .1, P > .20).
There were also no significant effects of current antipsychotic medication dosage or current smoking status (all
P > .15) on the RVI-AD scores in the discovery or replication datasets.
Discussion
Cognitive enhancing compounds have been tested as prospective frontline treatments for both SZ and AD but the
effort has thus far has met with costly failure.46 Identifying
the overlapping pathophysiological mechanisms for cognitive deficits in SZ and AD may guide and focus research
on effective treatments that target the shared deficits between them. We observed a striking similarity between
white matter deficit patterns in SZ and AD that are both
replicable and associated with core cognitive deficits in the
respective illnesses. The RVI-AD values were positively
correlated with age in patients but not in controls. Patients
started to show significantly higher RVI-AD in the fourth
201

Downloaded from https://academic.oup.com/schizophreniabulletin/article/47/1/197/5873334 by guest on 25 February 2021

Fig. 3. Significant age-related increases of RVI-AD values for schizophrenia (SZ) (A and B). *Significant after false discovery rates
(FDR) correction for multiple comparisons. Note: RVI, regional vulnerability index; AD, Alzheimer’s disease.

P. Kochunov et al

decade of life in the discovery cohort and during the fifth
decade in the replication cohort. In all 3 datasets (discovery, replication, and ADNI), higher RVI-AD values
were associated with worse neurocognitive performance.
Our findings propose bringing white matter-related biomarkers to the forefront of efforts to identify treatment
targets for cognitive deficits in both illnesses.
The significant correlation of white matter patientcontrol regional effect size patterns between SZ and AD
was driven by a significant reduction in the integrity of the
associative white matter tracts, including the ACR, FX,
and commissural fibers in the genu of corpus callosum
(GCC) and BCC while relatively sparing the motor and
sensory fibers such as the corticospinal tract and posterior
limb of the internal capsule in both SZ and AD (figure 1).
ACR, GCC, and BCC contain the primary fibers connecting the ipsilateral and interhemispheric prefrontal
cortex and are critical for higher cognitive functions.
202

Among all brain regions, the frontal white matter volume
had the largest evolutionary increase in humans compared
with other species,47 implying that the regions showing the
strongest impairment in both SZ and AD (figure 4C) are
also the phylogenetically most-expanded brain tissue in
humans. The FX is another associative fiber with substantial impairment in both SZ and AD. The FX fiber-tract
links the hippocampus with the lateral hypothalamus and
frontal cortical regions. Hippocampal shrinkage is a hallmark of AD,48,49 and hippocampal volume in SZ shows
the largest reduction among all subcortical regions.50
These neurobiological signatures common to SZ and AD
may explain their associations with similar regional deficit
patterns captured by the RVI approach.
RVI is a simple correlation between an individual and
the expected deficit pattern derived from a representative disease sample.32 The RVI is calculated after correcting the regional traits for age and sex. Therefore, the
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Fig. 4. On white matter tract level (A and B): A. Significant correlation of regional deficit (in Cohen’s d values) patterns across the 22
major white matter tracts for Alzheimer’s disease (AD; calculated from ADNI) and schizophrenia (SZ; calculated from ENIGMA). B.
No such correlation was observed between MCI and SZ. Similarly, on individual SZ patient level (C and D): C. regional vulnerability
index (RVI) for AD (calculated from ADNI) and RVI for SZ (calculated from ENIGMA) showed a robust correlation in SZ patients
(from the discovery sample, same below); D: correlation between RVI for MCI and RVI for SZ in SZ patients. Note: MCI, mild cognitive
impairment.

White Matter Schizophrenia and Alzheimer’s Disease

Another question is whether the overlapping white
matter regional deficit patterns in AD and SZ are related to general cognitive deficits and, therefore, nonspecific. However, the correlation between regional deficit
patterns in SZ and MCI was not significant (figure 4B).
Individuals with MCI have an unfavorable aging trajectory that leads to deficits in the FX,73,74 similar to AD and
SZ. However, MCI patients showed minimal deficits in
the ACR, GCC, BCC, and other associative tracts. The
specificity testing suggests that the sharing of deficit patterns between SZ and AD is not simply due to age-related
cognitive decline as in MCI.
We also observed that RVI-AD was positively correlated with age in SZ (figures 3A and 3B), such that the
similarity to AD in SZ patients became stronger with age.
This finding is consistent with recent “brain age” analyses showing that SZ had the largest accelerated aging
rate among all psychiatric illnesses (Cohen’s d = 0.54),
and AD has an even larger effect size (d = 1.03).75 This
may argue for the sharing of an age-related underlying
pathology for the 2 otherwise distinct illnesses.
Our study is limited by the lack of longitudinal data
to confirm if the RVI-AD score would track the risk for
dementia and cognitive decline in SZ patients. Only FA
was used to index white matter abnormalities and other
diffusion parameters were not explored. We chose FA
as it shows a higher sensitivity to SZ deficits compared
with other parameters.39 Additionally, the testing of RVIcognition associations was limited by differences in the
cognitive tests administered across the discovery and replication samples, especially the ADNI sample where the
cognitive tests were designed for the diagnosis of dementia
and, therefore, may suffer from score compression in
non-AD subjects due to ceiling effects. Lastly, a potential
explanation for the similarity of WM deficits in SZ and AD
is the use of antipsychotic medications in both disorders.
However, we consider this to be unlikely due to (1) the lack
of association between RVI and medication dose and (2)
the elevation of RVI-SZ values at the treatment initiation
stage.32 The latter suggests that white matter deficits are already established in patients prior to the treatment onset.
A shared aim in SZ and AD research is to discover
therapeutic interventions that can restore, prevent, or
slow down the progression of cognitive deficits in these
diseases. We demonstrated an unambiguous overlap in
white matter deficit patterns between SZ and AD. This
pattern was associated with the disease-related cognitive
deficits and appeared to be disease-specific. Development
of future treatments and therapies to prevent and treat
cognitive deficits in SZ and AD should consider targeting
white matter-related mechanisms.
Supplementary Material
Supplementary material is available at Schizophrenia
Bulletin.
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aging-related increases in RVI-AD in patients support
the heuristics of SZ as a progressive neurological disease
with an elevated risk of dementia.51–58 These heuristics are
further supported by evidence for the accelerated decline
of the associative white matter tracts in patients with
SZ.30,59,60 Thus, the higher white matter RVI-AD in SZ
patients is likely associated with detrimental interactions
between SZ risk factors and aging of cerebral white
matter. RVI does not measure the underlying neurobiological mechanisms. However, because RVI quantifies the
similarity of the anatomic deficit pattern to the representative disease pattern, it can capture shared brain deficit
patterns between different diseases and allow for the inference of intersecting anatomic mechanisms.
The hypothesis of similarity in the underlying mechanisms for the shared white matter deficits between AD
and SZ is still a subject to debate. Contemporary medicine has largely dismissed Kraepelin’s definition of SZ
as premature dementia61 due to the lack of evidence for
neurodegenerative cognitive decline in most SZ patients.6
The lack of amyloid-β and τ-protein pathologies in most
SZ postmortem studies further suggests nonoverlapping
pathophysiology.2,3 Despite these clear etiopathological
differences, neuroimaging studies have shown similarities
in deficits patterns between AD and SZ. For example, anatomical integrity in the temporal lobe and hippocampal
regions are highly impacted in both illness,62 yet the field
lacks robust comparative studies to determine if the
2 illnesses intersect as Kraepelin once delineated with
conviction. This question is revived by the evidence of
a higher risk for developing dementia in SZ.1 Using
modern imaging methods, our findings provide tantalizing evidence for a relationship between SZ and AD at
the white matter level.
In AD, white matter deficits can be secondary to neuronal amyloid-β and amyloid precursor protein accumulation63 in the frontal and temporal lobes that eventually
impact the associative tracts.64,65 In SZ, white mater
deficits may be due to the abnormal expression of oligodendrocyte lineage genes or oligodendrocyte cellular dysfunctions.66,67 The reciprocal rise in RVI-SZ in AD and
RVI-AD in SZ may reflect different underlying pathology
that converges on similar white matter structures as the
disorders progress.
Conversely, there are arguments for the sharing of etiological mechanisms between 2 disorders. For example, the
frontal white matter has high metabolic demands and is
vulnerable to cardiovascular risks.68,69 SZ patients have a
shorter lifespan, and the leading cause of their premature
mortality is cardiovascular diseases.70 In parallel, vascularrelated white matter damage predicts the development of
AD, leading to the emerging 2-hit theory on AD etiology,
whereby vascular insults constitute the first hit while the
accumulation of amyloid-β is the second.71,72 Therefore,
cardiovascular risks may present a common etiology to
explain the shared white matter deficit patterns.
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